Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: wrinkled (3), creased (4), ruled (587)

Carboplatin (AUC6) Retreat

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN Retreat Regimen (AUC6) • Ovary – Carboplatin (AUC6) Retreat Indication • Second line or subsequent treatment of platinum sensitive
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CarboplatinAUC6Retreat.pdf

UHS Inclusion and Belonging Strategy

Description: Our strategy sets out clear actions we will take to make UHS a place where every person feels they belong and
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/uhs-inclusion-and-belonging-strategy.pdf

Institutional information_2022-23_final

Description: Institutional information – key facts for inclusion as appropriate Support statements must be personal to your application to avoid the same document
Url: /Media/Southampton-Clinical-Research/Grants/Download/Institutional-information-2022-23-final.pdf

PV-CHP Cyclophosphamide-doxorubicin-polatuzumab vedotin -prednisolone

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-POLATUZUMAB VEDOTIN-PREDNISOLONE- RITUXIMAB Regimen • Lymphoma – Cyclophosphamide-doxorubicin-polatuzumab vedotin -prednisolone – rituximab Indication • Previously untreated diffuse
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/PV-CHP-Cyclophosphamide-doxorubicin-polatuzumab-vedotin-prednisolone.pdf

Carboplatin (AUC5)

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN (AUC5) Regimen • Ovary – Carboplatin (AUC 5) Indication • Adjuvant treatment in patients with moderate to high risk
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CarboplatinAUC5.pdf

Clofarabine

Description: Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA CLOFARABINE In-Patient Regimen Clofarabine not licensed in adult patients. This may require funding Regimen • Acute
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Clofarabine.pdf

Gilteritinib

Description: Chemotherapy Protocol Acute Myeloid Leukaemia GILTERITINIB Regimen  AML - Gilteritinib Indication Gilteritinib for treating relapsed/refractory FLT3 mutation positive myeloid leukaemia in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Gilteritinib.pdf

Carboplatin(AUC2)-Paclitaxel (7 day)

Description: A chemotherapy protocol on Carboplatin (AUC2) Paclitaxel.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/CarboplatinAUC2-Paclitaxel7day.pdf

Carboplatin (AUC6)

Description: Chemotherapy Protocol GYNAECOLOGICAL CANCER Regimen CARBOPLATIN (AUC6) 6 CYCLES  Ovary – Carboplatin (AUC6) 6 Cycles Indication  Adjuvant treatment in patients with moderate
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CarboplatinAUC6.pdf

Temsirolimus v1.1

Description: Chemotherapy Protocol RENAL CELL TEMSIROLIMUS This protocol may require funding Regimen Renal Cell - Temsirolimus Indication First line treatment of advanced renal
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Temsirolimus-v1.1.pdf

251 to 260 of 747

Previous … 24 25 26 27 28 … Next